Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come
Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come
Today's GLP-1 drug market consists primarily of semaglutide (Wegovy, Ozempic, and Rybelsus), owned by Novo Nordisk; and tirzepatide (Zepbound, Mounjaro), owned by Eli Lilly. All five of those drug brands, with the exception of Rybelsus, are administered by injection, whereas Rybelsus is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and Wegovy was also approved by the FDA in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more
塞馬盧肽正在被研究用於心臟病、阿爾茨海默病、肝病等多種應用
GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come
預計GLP-1藥物將在未來幾年產生數千億的營業收入
KELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following strategic update.
基洛納，BC / ACCESSWIRE / 2024年11月26日 / Lexaria Bioscience corp. (納斯達克：LEXX)(納斯達克：LEXXW)（"公司"或"Lexaria"），作爲全球藥物遞送平台的創新者，提供以下戰略更新。
Today's GLP-1 drug market consists primarily of semaglutide (Wegovy, Ozempic, and Rybelsus), owned by Novo Nordisk; and tirzepatide (Zepbound, Mounjaro), owned by Eli Lilly. All five of those drug brands, with the exception of Rybelsus, are administered by injection, whereas Rybelsus is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and Wegovy was also approved by the FDA in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.
今天的GLP-1藥物市場主要由塞馬盧肽（Wegovy、Ozempic和Rybelsus）構成，屬於諾和諾德；以及提澤帕肽（Zepbound、Mounjaro），屬於禮來。除了Rybelsus之外的那五種藥物品牌，均通過注射給藥，而Rybelsus是目前FDA批准的唯一口服藥片。雖然這兩種藥物最初獲得FDA批准用於糖尿病管理，但不久之後就獲得了減重批准，Wegovy還在2024年3月獲得FDA批准，以降低心血管死亡、心臟病發作和中風的風險。
Acceptance and use of these two drugs by the public has resulted in unprecedented demand, with estimates of 2024 revenue between them of ~$30 billion, compared to just $300 million in 2018, an increase of 100x or 10,000%.
公衆接受和使用這兩種藥物導致了前所未有的需求，預計2024年的營業收入將在30億美元左右，而2018年僅爲3000萬美元，增長了100倍或10,000%。
譯文內容由第三人軟體翻譯。
